CVE:MDP

Medexus Pharmaceuticals Competitors

C$6.80

-0.22 (-3.13 %)

(As of 03/5/2021 03:59 PM ET)

Add

Compare

Today's Range

C$6.55

Now: C$6.80▼

C$7.38

50-Day Range

C$6.96

MA: C$7.99▼

C$9.70

52-Week Range

C$1.42

Now: C$6.80▼

C$9.75

Volume91,729 shs

Average Volume90,818 shs

Market CapitalizationC$129.82 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Medexus Pharmaceuticals (CVE:MDP) Vs. EPI, WMD, NINE, ASP, FLWR, and RX

Should you be buying MDP stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Medexus Pharmaceuticals, including ESSA Pharma (EPI), WeedMD (WMD), Delta 9 Cannabis (NINE), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), and BioSyent Inc. (RX.V) (RX).

Medexus Pharmaceuticals vs. ESSA Pharma Stock

Medexus Pharmaceuticals (CVE:MDP) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Medexus Pharmaceuticals and ESSA Pharma's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$108.29 million	1.20	C$-34,573,801.00	C($1.81)	-3.75
ESSA Pharma	N/A	N/A	N/A	C($0.99)	-8.27

ESSA Pharma has lower revenue, but higher earnings than Medexus Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medexus Pharmaceuticals and ESSA Pharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	N/A	N/A	N/A
ESSA Pharma	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Medexus Pharmaceuticals and ESSA Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0	0	2	0	3.00
ESSA Pharma	0	0	0	0	N/A

Medexus Pharmaceuticals presently has a consensus price target of C$5.00, suggesting a potential downside of 26.47%. Given Medexus Pharmaceuticals' higher possible upside, research analysts plainly believe Medexus Pharmaceuticals is more favorable than ESSA Pharma.

Summary

Medexus Pharmaceuticals beats ESSA Pharma on 4 of the 5 factors compared between the two stocks.

Medexus Pharmaceuticals vs. WeedMD Stock

Medexus Pharmaceuticals (CVE:MDP) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Medexus Pharmaceuticals and WeedMD's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$108.29 million	1.20	C$-34,573,801.00	C($1.81)	-3.75
WeedMD	C$27.21 million	3.25	C$-18,540,456.00	C($0.09)	-4.77

WeedMD has lower revenue, but higher earnings than Medexus Pharmaceuticals. WeedMD is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medexus Pharmaceuticals and WeedMD's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	N/A	N/A	N/A
WeedMD	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Medexus Pharmaceuticals and WeedMD, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0	0	2	0	3.00
WeedMD	0	1	0	0	2.00

Medexus Pharmaceuticals presently has a consensus price target of C$5.00, suggesting a potential downside of 26.47%. WeedMD has a consensus price target of C$0.58, suggesting a potential upside of 36.90%. Given WeedMD's higher possible upside, analysts clearly believe WeedMD is more favorable than Medexus Pharmaceuticals.

Medexus Pharmaceuticals vs. Delta 9 Cannabis Stock

Medexus Pharmaceuticals (CVE:MDP) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Medexus Pharmaceuticals and Delta 9 Cannabis' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	N/A	N/A	N/A
Delta 9 Cannabis	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Medexus Pharmaceuticals and Delta 9 Cannabis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0	0	2	0	3.00
Delta 9 Cannabis	0	0	0	0	N/A

Medexus Pharmaceuticals presently has a consensus price target of C$5.00, suggesting a potential downside of 26.47%. Given Medexus Pharmaceuticals' higher possible upside, equities analysts clearly believe Medexus Pharmaceuticals is more favorable than Delta 9 Cannabis.

Earnings and Valuation

This table compares Medexus Pharmaceuticals and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$108.29 million	1.20	C$-34,573,801.00	C($1.81)	-3.75
Delta 9 Cannabis	C$12.87 million	6.94	C$4.69 million	C$0.05	19.07

Delta 9 Cannabis has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Medexus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Medexus Pharmaceuticals vs. Acerus Pharmaceuticals Stock

Acerus Pharmaceuticals (TSE:ASP) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares Acerus Pharmaceuticals and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	N/A	N/A	N/A
Medexus Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Acerus Pharmaceuticals and Medexus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acerus Pharmaceuticals	0	0	0	0	N/A
Medexus Pharmaceuticals	0	0	2	0	3.00

Medexus Pharmaceuticals has a consensus target price of C$5.00, suggesting a potential downside of 26.47%. Given Medexus Pharmaceuticals' higher possible upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than Acerus Pharmaceuticals.

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	C$1.33 million	57.89	C$-44,590,052.00	C($0.03)	-1.72
Medexus Pharmaceuticals	C$108.29 million	1.20	C$-34,573,801.00	C($1.81)	-3.75

Medexus Pharmaceuticals has higher revenue and earnings than Acerus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Medexus Pharmaceuticals beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Medexus Pharmaceuticals vs. The Flowr Stock

The Flowr (CVE:FLWR) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares The Flowr and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
The Flowr	N/A	N/A	N/A
Medexus Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for The Flowr and Medexus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Flowr	0	0	0	0	N/A
Medexus Pharmaceuticals	0	0	2	0	3.00

The Flowr presently has a consensus target price of C$0.70, suggesting a potential upside of 125.81%. Medexus Pharmaceuticals has a consensus target price of C$5.00, suggesting a potential downside of 26.47%. Given The Flowr's higher possible upside, research analysts clearly believe The Flowr is more favorable than Medexus Pharmaceuticals.

Earnings & Valuation

This table compares The Flowr and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Flowr	C$5.96 million	17.13	C$-128,870,081.00	C($0.39)	-0.79
Medexus Pharmaceuticals	C$108.29 million	1.20	C$-34,573,801.00	C($1.81)	-3.75

Medexus Pharmaceuticals has higher revenue and earnings than The Flowr. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Summary

The Flowr beats Medexus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Medexus Pharmaceuticals vs. BioSyent Inc. (RX.V) Stock

BioSyent Inc. (RX.V) (CVE:RX) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares BioSyent Inc. (RX.V) and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioSyent Inc. (RX.V)	N/A	N/A	N/A
Medexus Pharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares BioSyent Inc. (RX.V) and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioSyent Inc. (RX.V)	C$22.18 million	4.22	C$4.10 million	C$0.32	22.81
Medexus Pharmaceuticals	C$108.29 million	1.20	C$-34,573,801.00	C($1.81)	-3.75

BioSyent Inc. (RX.V) has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent Inc. (RX.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioSyent Inc. (RX.V) and Medexus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioSyent Inc. (RX.V)	0	2	0	0	2.00
Medexus Pharmaceuticals	0	0	2	0	3.00

BioSyent Inc. (RX.V) presently has a consensus target price of C$7.00, suggesting a potential downside of 4.11%. Medexus Pharmaceuticals has a consensus target price of C$5.00, suggesting a potential downside of 26.47%. Given BioSyent Inc. (RX.V)'s higher possible upside, research analysts clearly believe BioSyent Inc. (RX.V) is more favorable than Medexus Pharmaceuticals.

Summary

BioSyent Inc. (RX.V) beats Medexus Pharmaceuticals on 5 of the 8 factors compared between the two stocks.